Erste Asset Management GmbH boosted its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) by 47.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 739,332 shares of the company’s stock after acquiring an additional 239,332 shares during the quarter. Erste Asset Management GmbH owned 1.29% of Ginkgo Bioworks worth $6,979,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at $29,000. KBC Group NV purchased a new stake in Ginkgo Bioworks in the 4th quarter valued at about $31,000. Palumbo Wealth Management LLC bought a new position in Ginkgo Bioworks in the 4th quarter worth about $144,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Ginkgo Bioworks during the fourth quarter worth approximately $154,000. Finally, SVB Wealth LLC bought a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $171,000. Institutional investors own 78.63% of the company’s stock.
Ginkgo Bioworks Stock Down 2.9 %
Shares of NYSE:DNA opened at $6.46 on Friday. The business’s 50 day moving average is $11.15 and its 200 day moving average is $9.20. The stock has a market cap of $374.61 million, a P/E ratio of -0.49 and a beta of 1.23. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.26 and a 52-week high of $48.00.
Ginkgo Bioworks Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
- Five stocks we like better than Ginkgo Bioworks
- Using the MarketBeat Dividend Yield Calculator
- 3 Undervalued Stocks You Can Buy at a Discount Now
- How to Invest in Biotech Stocks
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What Are the FAANG Stocks and Are They Good Investments?
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.